You are here: Industry Insights > Regeneron

News List

Regeneron, Zai Lab Enter Strategic REGN1979 Alliance contractpharma
April 09, 2020
Regeneron will receive $30 million upfront and is eligible to receive up to $160 million in additional regulatory and sales milestones.
First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19 worldpharmanews
April 03, 2020
The first patient outside of the U.S. has been treated as part of a global clinical program evaluating Kevzara® (sarilumab) in patients hospitalized with severe COVID-19.
Clinical programme to evaluate Kevzara® as COVID-19 treatment begins europeanpharmaceuticalreview
March 19, 2020
Led by Sanofi and Regeneron, clinical trials to examine Kevzara (sarilumab) as an effective COVID-19 treatment will begin in the US.
Regeneron Advances COVID-19 Development Efforts contractpharma
March 18, 2020
Isolates hundreds of virus-neutralizing, human antibodies; will prepare manufacturing-ready cell lines so that clinical-scale production can begin immediately.
Sanofi and Regeneron trial Kevzara to treat severe Covid-19 pharmaceutical-technology
March 17, 2020
Sanofi and Regeneron Pharmaceuticals have initiated a clinical programme of rheumatoid arthritis drug Kevzara (sarilumab) to treat hospitalised patients with severe Covid-19 coronavirus infection.
Sanofi and Regeneron to assess Kevzara to treat Covid-19 pharmaceutical-technology
March 12, 2020
Sanofi and Regeneron Pharmaceuticals have plans to initiate clinical trials of rheumatoid arthritis drug Kevzara for the treatment of Covid-19 symptoms.
Regeneron Announces Phase 2 Results for Garetosmab americanpharmaceuticalreview
January 14, 2020
Regeneron Pharmaceuticals announced results from LUMINA-1, a 44-patient, Phase 2, double-blind placebo-controlled trial evaluating garetosmab (REGN2477) in patients with fibrodysplasia ossificans progressiva (FOP).
Regeneron to lay off field staffers as it restructures Sanofi partnership fiercepharma
January 03, 2020
With its long-standing partnership with Sanofi in its final days, Regeneron is in a belt-tightening phase as it prepares for its new reality.
Regeneron Announces Positive Topline Data with Anti-C5 Antibody Pozelimab americanpharmaceuticalreview
December 12, 2019
Regeneron Pharmaceuticals announced topline data from the pozelimab (REGN3918) Phase 2 clinical program in paroxysmal nocturnal hemoglobinuria (PNH) ...
Sanofi and Regeneron to simplify antibody partnership pharmaceutical-technology
December 12, 2019
Sanofi and Regeneron Pharmaceuticals have said the companies may transform their antibody partnership, which involves Kevzara (sarilumab) and Praluent (alirocumab) drugs ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page